Cargando…
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial
Ticagrelor has a greater antiplatelet efficacy than clopidogrel but may be accompanied by an increased risk of bleeding. This study evaluated the antiplatelet effect and pharmacokinetic profile of low-dose ticagrelor in healthy Chinese volunteers. Thirty healthy subjects were randomized to receive s...
Autores principales: | Li, Pan, Gu, Ying, Yang, Yawei, Chen, Lizhi, Liu, Junmei, Gao, Lihong, Qin, Yongwen, Cai, Quancai, Zhao, Xianxian, Wang, Zhuo, Ma, Liping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995486/ https://www.ncbi.nlm.nih.gov/pubmed/27554803 http://dx.doi.org/10.1038/srep31838 |
Ejemplares similares
-
Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial
por: Li, Pan, et al.
Publicado: (2015) -
Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013) -
Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010) -
Ticagrelor: The first approved reversible oral antiplatelet agent
por: Goel, Divya
Publicado: (2013) -
Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
por: Condello, Francesco, et al.
Publicado: (2021)